Safety and Efficacy of RSV Vaccines in Older Adults

Author(s):

Carrie Koenigsfeld, PharmD, FAPhA

Key Takeaways

ConquerRSV, AReSVi-006, and RENOIR trials show significant efficacy in preventing RSV-related illness in older adults.
The vaccines have demonstrated generally well-tolerated safety profiles with manageable side effects.
Immunogenicity and protective benefits data support the potential role of these vaccines in reducing RSV burden.
Ongoing monitoring and research are crucial for optimizing vaccine strategies and ensuring long-term safety.

Carrie Koenigsfeld, PharmD, FAPhA, discusses the RSV vaccines currently available for older adults, highlighting the efficacy and safety profiles of the ConquerRSV, AReSVi-006, and RENOIR trials.

EP: 1.What Is RSV?

EP: 2.Older Adults, High-Risk Populations, and Severe Illness

Now Viewing

EP: 3.Safety and Efficacy of RSV Vaccines in Older Adults

EP: 4.Vaccine Hesitancy and Patient Counseling Techniques

EP: 5.Strategies for Incorporating Vaccinations into Pharmacy Workflows

EP: 6.Vaccination Community Outreach Initiatives

Video content above is prompted by the following:

Provide an overview of the RSV vaccines currently available for older adults, highlighting the efficacy and safety profiles of the ConquerRSV, AReSVi-006, and RENOIR trials.

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!